Efficacy of multiple fraction conventional radiation therapy for painful uncomplicated bone metastases: A systematic review

• Published in: Radiotherapy and oncology Vol. 122; no. 3; pp. 323 - 331
• Main Authors: Chow, Ronald, Hoskin, Peter, Chan, Stephanie, Mesci, Aruz, Hollenberg, Drew, Lam, Henry, DeAngelis, Carlo, Chow, Edward
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.03.2017
• Subjects: Bone metastases; Bone Neoplasms - complications; Bone Neoplasms - radiotherapy; Bone Neoplasms - secondary; Dose Fractionation; Hematology, Oncology and Palliative Medicine; Humans; Multiple-fraction; Pain - etiology; Pain Management - methods; Pain response; Palliative Care; Palliative radiotherapy; Pain response; Palliative radiotherapy; Multiple-fraction; Bone metastases
• ISSN: 0167-8140; 1879-0887
• DOI: 10.1016/j.radonc.2016.12.031

Abstract Background: Radiation therapy is effective for painful uncomplicated bone metastases, with multiple fraction radiation therapy (MFRT) administered frequently. The optimal dose for MFRT to yield maximum pain relief remains unclear. The aim of this systematic review was to determine pain response across MFRT doses. Methods: A literature search was conducted in Ovid MEDLINE(R) <1946 to July Week 3 2016>, Embase Classic & Embase <1947 to 2016 Week 30> and Cochrane Central Register of Controlled Trials <June 2016>. Pain response rates and the side effects for MFRT doses were extracted. Results: From the 3719 articles identified from the search, 17 were included for quantitative synthesis. 22.5 Gy/5 had the highest overall response (OR) rate, 30 Gy/15 had better complete response (CR) rate and 20 Gy/2 had better partial response (PR) rate. Only 4 of the 17 included studies directly compared MFRT doses with each other – one reported marginally-better OR for 24 Gy/6 over 20 Gy/2; another found 20 Gy/10 to be slightly more efficacious than 30 Gy/15 and 22.5 Gy/5 for OR. Two randomized trials compared 20 Gy/5 and 30 Gy/10 – one favored 20 Gy/5 while the other concluded 30 Gy/10 to be the better option. The overall rate of GI toxicities, nausea, and vomiting did not differ greatly between MFRT doses. Conclusion: No major difference exists between the schedules and toxic events studied in these trials. This is consistent with the wealth of randomized data which show no dose response for pain relief after radiotherapy for metastatic bone pain.